GeneDx Holdings (WGS) Other Operating Expenses (2021 - 2024)

GeneDx Holdings has disclosed Other Operating Expenses across 4 years of filings, most recently posting $2.6 million for Q4 2024.

• In Q4 2024, Other Operating Expenses fell 20.59% year-over-year to $2.6 million; the TTM figure through Sep 2025 stood at $2.6 million (up 285.59% YoY), while the FY2023 annual figure was -$2.0 million, up 69.0% from the prior year.
• Other Operating Expenses advanced to $2.6 million in Q4 2024, from -$774000.0 in the prior quarter.
• Over the last five years, Other Operating Expenses for WGS reached as high as $13.0 million in Q2 2021 and fell as low as -$2.8 million in Q3 2023.
• The 4-year median for Other Operating Expenses is -$874000.0 (2024), against an average of $705080.0.
• The widest YoY moves for Other Operating Expenses: up 306.38% in 2023, down 64.64% in 2023.
• A 4-year view of Other Operating Expenses shows it stood at $13.0 million in 2021, then tumbled by 112.3% to -$1.6 million in 2022, then soared by 306.38% to $3.3 million in 2023, then dropped by 20.59% to $2.6 million in 2024.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $2.6 million, -$774000.0, and -$874000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.